215 related articles for article (PubMed ID: 28209190)
1. The effects of different familial Alzheimer's disease mutations on APP processing in vivo.
Thordardottir S; Kinhult Ståhlbom A; Almkvist O; Thonberg H; Eriksdotter M; Zetterberg H; Blennow K; Graff C
Alzheimers Res Ther; 2017 Feb; 9(1):9. PubMed ID: 28209190
[TBL] [Abstract][Full Text] [Related]
2. Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.
Zhang C; Browne A; Kim DY; Tanzi RE
Curr Alzheimer Res; 2010 Feb; 7(1):21-6. PubMed ID: 20205669
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease.
Pera M; Alcolea D; Sánchez-Valle R; Guardia-Laguarta C; Colom-Cadena M; Badiola N; Suárez-Calvet M; Lladó A; Barrera-Ocampo AA; Sepulveda-Falla D; Blesa R; Molinuevo JL; Clarimón J; Ferrer I; Gelpi E; Lleó A
Acta Neuropathol; 2013 Feb; 125(2):201-13. PubMed ID: 23224319
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study.
Thordardottir S; Almkvist O; Johansson C; Zetterberg H; Blennow K; Graff C
J Alzheimers Dis; 2020; 76(3):941-953. PubMed ID: 32568193
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-β
Perrone F; Bjerke M; Hens E; Sieben A; Timmers M; De Roeck A; Vandenberghe R; Sleegers K; Martin JJ; De Deyn PP; Engelborghs S; van der Zee J; Van Broeckhoven C; Cacace R;
Alzheimers Res Ther; 2020 Sep; 12(1):108. PubMed ID: 32917274
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.
Schilling S; Pradhan A; Heesch A; Helbig A; Blennow K; Koch C; Bertgen L; Koo EH; Brinkmalm G; Zetterberg H; Kins S; Eggert S
Acta Neuropathol Commun; 2023 Jun; 11(1):87. PubMed ID: 37259128
[TBL] [Abstract][Full Text] [Related]
7. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
8. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.
Reinert J; Richard BC; Klafki HW; Friedrich B; Bayer TA; Wiltfang J; Kovacs GG; Ingelsson M; Lannfelt L; Paetau A; Bergquist J; Wirths O
Acta Neuropathol Commun; 2016 Mar; 4():24. PubMed ID: 26955942
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.
Ringman JM; Coppola G; Elashoff D; Rodriguez-Agudelo Y; Medina LD; Gylys K; Cummings JL; Cole GM
Dement Geriatr Cogn Disord; 2012; 33(1):1-5. PubMed ID: 22343824
[TBL] [Abstract][Full Text] [Related]
10. Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset.
Petit D; Fernández SG; Zoltowska KM; Enzlein T; Ryan NS; O'Connor A; Szaruga M; Hill E; Vandenberghe R; Fox NC; Chávez-Gutiérrez L
Mol Psychiatry; 2022 Jun; 27(6):2821-2832. PubMed ID: 35365805
[TBL] [Abstract][Full Text] [Related]
11. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
Lanoiselée HM; Nicolas G; Wallon D; Rovelet-Lecrux A; Lacour M; Rousseau S; Richard AC; Pasquier F; Rollin-Sillaire A; Martinaud O; Quillard-Muraine M; de la Sayette V; Boutoleau-Bretonniere C; Etcharry-Bouyx F; Chauviré V; Sarazin M; le Ber I; Epelbaum S; Jonveaux T; Rouaud O; Ceccaldi M; Félician O; Godefroy O; Formaglio M; Croisile B; Auriacombe S; Chamard L; Vincent JL; Sauvée M; Marelli-Tosi C; Gabelle A; Ozsancak C; Pariente J; Paquet C; Hannequin D; Campion D;
PLoS Med; 2017 Mar; 14(3):e1002270. PubMed ID: 28350801
[TBL] [Abstract][Full Text] [Related]
12. Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations.
Kim M; Bezprozvanny I
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948396
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Non-Amyloidogenic Mutations in APP Supports Loss of Function Hypothesis of Alzheimer's Disease.
Kim M; Bezprozvanny I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768421
[TBL] [Abstract][Full Text] [Related]
14. Findings from the Swedish Study on Familial Alzheimer's Disease Including the APP Swedish Double Mutation.
Thordardottir S; Graff C
J Alzheimers Dis; 2018; 64(s1):S491-S496. PubMed ID: 29614673
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.
Li X; Westman E; Thordardottir S; Ståhlbom AK; Almkvist O; Blennow K; Wahlund LO; Graff C
J Alzheimers Dis; 2017; 56(1):327-334. PubMed ID: 27911308
[TBL] [Abstract][Full Text] [Related]
16. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.
Suárez-Calvet M; Belbin O; Pera M; Badiola N; Magrané J; Guardia-Laguarta C; Muñoz L; Colom-Cadena M; Clarimón J; Lleó A
J Neurochem; 2014 Jan; 128(2):330-9. PubMed ID: 24117942
[TBL] [Abstract][Full Text] [Related]
17. Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype.
O'Connor A; Pannee J; Poole T; Arber C; Portelius E; Swift IJ; Heslegrave AJ; Abel E; Willumsen N; Rice H; Weston PSJ; Ryan NS; Polke JM; Nicholas JM; Mead S; Wray S; Chávez-Gutiérrez L; Frost C; Blennow K; Zetterberg H; Fox NC
Brain; 2021 Nov; 144(10):2964-2970. PubMed ID: 33892504
[TBL] [Abstract][Full Text] [Related]
18. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
[TBL] [Abstract][Full Text] [Related]
19. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
20. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
